{"id":"reversal-of-superficial-neuromuscular-blockade","safety":{"commonSideEffects":[{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Increased salivation"},{"rate":null,"effect":"Muscle fasciculations"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1200527","moleculeType":"Small molecule","molecularWeight":"1243.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Neuromuscular blocking agents are used during anesthesia to paralyze muscles; reversal agents work by either inhibiting acetylcholinesterase (allowing acetylcholine to accumulate and compete with the blocking agent) or by acting as selective relaxant binding agents that encapsulate and inactivate the blocking drug. This restores neuromuscular transmission and allows spontaneous breathing and muscle function to return.","oneSentence":"This drug reverses neuromuscular blockade by antagonizing the effects of neuromuscular blocking agents at the neuromuscular junction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:52.334Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reversal of superficial neuromuscular blockade induced by neuromuscular blocking agents during general anesthesia"}]},"trialDetails":[{"nctId":"NCT05841316","phase":"","title":"The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block","status":"UNKNOWN","sponsor":"Ankara University","startDate":"2023-10","conditions":"Deep Neuromuscular Blockade, Anesthesia, General","enrollment":40},{"nctId":"NCT04920682","phase":"PHASE4","title":"Reversal of Moderate or Superficial Neuromuscular Blockade Induced by Cisatracurium","status":"COMPLETED","sponsor":"Pontificia Universidade Catolica de Sao Paulo","startDate":"2021-06-01","conditions":"Neostigmine, Neuromuscular Blocking Agents, Muscle Weakness","enrollment":60},{"nctId":"NCT01440933","phase":"PHASE2","title":"Efficacy of Sugammadex in Magnesium Pretreated Patients","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2011-09","conditions":"Neuromuscular Block","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Reversal of superficial neuromuscular blockade","genericName":"Reversal of superficial neuromuscular blockade","companyName":"Pontificia Universidade Catolica de Sao Paulo","companyId":"pontificia-universidade-catolica-de-sao-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug reverses neuromuscular blockade by antagonizing the effects of neuromuscular blocking agents at the neuromuscular junction. Used for Reversal of superficial neuromuscular blockade induced by neuromuscular blocking agents during general anesthesia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}